Literature DB >> 25998619

Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy.

Shyamala Maheswaran1, Daniel A Haber1.   

Abstract

With increasing application of targeted therapies and the development of acquired resistance, much attention is being focused on developing in vitro and in vivo patient-specific tumor models for individualized therapeutic evaluation of cancers. Circulating tumor cells provide a source of noninvasively and sequentially sampled invasive cancer cells suitable for propagation in vitro. We review the advantages and challenges associated with ex vivo culture of tumor cells circulating in the blood of patients with cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25998619      PMCID: PMC4470788          DOI: 10.1158/0008-5472.CAN-15-0145

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture.

Authors:  Jacob O Fierer; Gianluca Veggiani; Mark Howarth
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

2.  In vitro drug assay: pharmacologic considerations.

Authors:  D S Alberts; H S Chen; S E Salmon
Journal:  Prog Clin Biol Res       Date:  1980

3.  Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.

Authors:  Zhian Liu; Alberto Fusi; Alexander Schmittel; Ingeborg Tinhofer; Achim Schneider; Ulrich Keilholz
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  Velocity effect on aptamer-based circulating tumor cell isolation in microfluidic devices.

Authors:  Yuan Wan; Jifu Tan; Waseem Asghar; Young-tae Kim; Yaling Liu; Samir M Iqbal
Journal:  J Phys Chem B       Date:  2011-11-07       Impact factor: 2.991

5.  Prostate cancer and other xenografts from cells in peripheral blood of patients.

Authors:  T G Pretlow; S Schwartz; J M Giaconia; A L Wright; H A Grimm; N L Edgehouse; J R Murphy; S D Markowitz; J M Jamison; J L Summers; C R Hamlin; G T MacLennan; M I Resnick; T P Pretlow; C F Connell
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

6.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

7.  Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells.

Authors:  Liying Yang; James C Lang; Priya Balasubramanian; Kris R Jatana; David Schuller; Amit Agrawal; Maciej Zborowski; Jeffrey J Chalmers
Journal:  Biotechnol Bioeng       Date:  2009-02-01       Impact factor: 4.530

Review 8.  Circulating tumor cells: approaches to isolation and characterization.

Authors:  Min Yu; Shannon Stott; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  J Cell Biol       Date:  2011-02-07       Impact factor: 10.539

9.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

10.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

View more
  39 in total

Review 1.  Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

Authors:  Silvia Calabuig-Fariñas; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Carlos Camps
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 2.  Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.

Authors:  Xiaofen Zhang; Shaoqing Ju; Xudong Wang; Hui Cong
Journal:  Clin Exp Med       Date:  2019-06-12       Impact factor: 3.984

Review 3.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Authors:  Christopher M Hartshorn; Michelle S Bradbury; Gregory M Lanza; Andre E Nel; Jianghong Rao; Andrew Z Wang; Ulrich B Wiesner; Lily Yang; Piotr Grodzinski
Journal:  ACS Nano       Date:  2017-12-22       Impact factor: 15.881

Review 4.  Liquid biopsy for brain tumors.

Authors:  Ganesh M Shankar; Leonora Balaj; Shannon L Stott; Brian Nahed; Bob S Carter
Journal:  Expert Rev Mol Diagn       Date:  2017-09-06       Impact factor: 5.225

5.  Microfluidic isolation of platelet-covered circulating tumor cells.

Authors:  Xiaocheng Jiang; Keith H K Wong; Aimal H Khankhel; Mahnaz Zeinali; Eduardo Reategui; Matthew J Phillips; Xi Luo; Nicola Aceto; Fabio Fachin; Anh N Hoang; Wooseok Kim; Annie E Jensen; Lecia V Sequist; Shyamala Maheswaran; Daniel A Haber; Shannon L Stott; Mehmet Toner
Journal:  Lab Chip       Date:  2017-10-11       Impact factor: 6.799

6.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

Review 7.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08

Review 8.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 9.  [Current progress in research of circulating tumor cells].

Authors:  Qian-Wen Zhao; Bo Situ; Lei Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

Review 10.  Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.

Authors:  Tian Zhang; Andrew J Armstrong
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.